Our Experience with Ustekinumab for the Treatment of Psoriasis
Authors:
N. Vojáčková; J. Fialová; Z. Kružicová; J. Hercogová
Authors‘ workplace:
Dermatovenerologická klinika 2. LF UK a FN Na Bulovce
přednosta prof. MUDr. Jana Hercogová, CSc.
Published in:
Čes-slov Derm, 86, 2011, No. 4, p. 198-202
Category:
Case Reports
Overview
Three cases of patients with severe chronic plaque psoriasis in whom classical systemic therapy failed or was discontinued due to side effects are described. After three months of ustekinumab administration more than a year-long remission was achieved in all cases. The therapy is tolerated well, followed laboratory tests are within normal range. Authors draw attention to the new biological agent in the treatment of severe plaque psoriasis.
Key words:
biological therapy – ustekinumab – effectiveness – safety
Sources
1. BENÁKOVÁ, N., ŠTORK, J. Léčba psoriázy biologiky. Konsenzuální doporučené postupy České dermatologické společnosti ČLS JEP 2006. Čes.-slov. Derm., 81, 2006, 4, s. 1–11.
2. BENÁKOVÁ, N., ŠTORK, J. Novinky v léčbě psoriázy biologiky a standardními systémovými léky. Čes.-slov. Derm., 2008, 83, 4, s. 191–202.
3. BOEHNCKE, W. H., KATSAMBAS, A., ORTONNE, J. P. et al. EADV preceptorship: advances in dermatology. JEADV, 2010, 24, Suppl. 5, p. 2–24.
4. FIALOVÁ, J., HERCOGOVÁ, J. Psoriáza. Postgraduální medicína, 2010, 12, 4, s. 435–442.
5. GRIFFTHS, A., STROBER, B. E., VAN DE KERKHOF, P. et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N. Engl. J. Med., 2010, 362, p. 118–128.
6. GOTTLIEB, A., MENTER, A., MENDELSOHN, A. et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet, 2009, 373, p. 633–640.
7. HERCOGOVÁ, J. Biologická léčba psoriázy. Postgraduální medicína, 2010, 12, 2, s. 132–138.
8. HERCOGOVA, J., RICCERI, F., TRIPO, L., LOTTI, T., PRIGNANO, F. Psoriasis and body mass index. Dermatol. Therapy., 2010, 23, 2, p. 152–154.
9. LEONARDI, C., KIMBALL, A. B., PAPP, K. A. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet, 2008, 371, p. 1665–1674.
10. LOTTI, T., DELESCLUSE, J., HERCOGOVA, J. Established treatments for psoriasis. A critical review. Int. J. Immunopathol. Pharmacol. Sec. Dermatol., 2002, 13, Suppl. 1, p. 5–10.
11. LOTTI, T., HERCOGOVA, J., PRIGNANO, F. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? Dermatol. Therapy, 2010, 23, 2, p. 119–122.
12. MENTER, A., KORMAN, N., ELMETS, C. A. et al. Guidelines of care for management of psoriasis and psoriatic arthritis. J. Am. Acad. Dermatol., 2011, in press 10.1016/j.jaad.2010.11.055.
13. NĚMCOVÁ, A., FIALOVÁ, J., HERCOGOVÁ, J. Závažný typ psoriázy s výrazným psychickým postižením léčený efalizumabem. Čes.-slov. Derm., 2008, 83, 1, s. 33–36.
14. PAPP, K. A., LANGLEY, R. G., LEBWOHL, M. et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet, 2008, 371, p. 1675–1684.
15. PIETRZAK, A., CHODOROWSKA, G., SZEPIETOWSKI, J., ZALEWSKA-JANOWSKA, A., KRASOWSKA, D., HERCOGOVA, J. Psoriasis and serum lipid abnormalities. Review Dermatol. Therapy, 2010, 23, 2, p. 160–173.
16. REICH, K. Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis:Results of integrated analyses of data from phase II and III clinical studies. Br. J. Dermatol., 2011, in press.
Labels
Dermatology & STDs Paediatric dermatology & STDsArticle was published in
Czech-Slovak Dermatology
2011 Issue 4
Most read in this issue
- Immunofluorescence in Dermatology
- Red Sea Coral Contact Dermatitis
- Psoriasis-like Skin Reactions during TNF-α Blockers Therapy
- Our Experience with Ustekinumab for the Treatment of Psoriasis